Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
A-Share Information
H-Share Information
2020.04.29
2019年年度报告摘要
2020.04.29
关于公司募集资金年度存放与实际使用情况的鉴证报告
2020.04.29
内部控制审计报告
2020.04.29
关于前期会计差错更正及追溯调整的公告
2020.04.29
2019年度商誉减值测试报告
2020.04.29
中天国富证券有限公司关于公司2019年度募集资金存放与使用情况的专项核查意见
2020.04.29
2019年度募集资金存放与使用情况的专项报告
2020.04.21
第四届董事会第三十二次会议决议公告
2020.04.21
关于首次公开发行境外上市外资股（H股）获得中国证监会批复的公告
第一页
上一页
62
63
64
65
66
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
